Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 9 · below the Ichimoku cloud · RSI 36 · MACD below its signal
None of the 29 investors followed here reported a position in GRI in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a GRI trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -52.9 | -21.8 | -10.2 | -4.8 | -5.5 | -14.1 | -22.0 | 39.1 | 0.5 | -19.7 | −77.6% | ||
| 2025 | -23.7 | -26.3 | -59.6 | -43.1 | -25.8 | -4.4 | -0.8 | 8.6 | 48.2 | -17.5 | 17.6 | -87.7 | −98.2% |
| 2024 | -39.9 | -50.6 | -5.1 | -43.6 | -29.6 | -51.1 | -60.2 | -33.6 | -28.9 | 143.2 | -22.1 | 21.1 | −97.6% |
| 2023 | -7.6 | 67.9 | -19.6 | -36.0 | -14.0 | -28.9 | -15.6 | -64.6 | 22.0 | -21.3 | -49.9 | -37.0 | −95.6% |
| 2022 | -18.4 | 51.4 | -74.6 | -34.0 | -54.0 | 12.3 | -37.5 | 2.5 | -30.5 | -11.2 | -2.4 | 17.4 | −95.2% |
| 2021 | -24.1 | -7.8 | -6.5 | 36.0 | -15.6 | 53.2 | 3.4 | -34.5 | 14.9 | 9.3 | −2.1% |
No insider transactions reported for GRI.
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells that is in preclinical development for the treatment of autoimmune disorders; a proprietary library of 500+ compounds; and GRI-0124 and GRI-0729 for balance inflammatory immune responses. The company was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.
Buy / hold / sell counts